Physician profile
Ken Eugene Crider
NPI 1831114172
$1,035.29
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $562 · 2021: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $252.62 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $179.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.30 | 2019-2020 | |
| Amarin Pharma, INC. | $92.27 | 2019-2020 | |
| Astellas Pharma US INC | $86.37 | 2019-2021 | |
| Amgen INC. | $55.92 | 2019-2020 | |
| Pfizer INC. | $52.82 | 2019 | |
| Lilly USA, LLC | $49.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.57 | 2019-2020 | |
| Mylan Specialty L.P. | $32.06 | 2020-2021 | |
| Gilead Sciences, INC. | $29.47 | 2019-2020 | |
| Allergan, INC. | $27.34 | 2020 | |
| Merck Sharp & Dohme LLC | $23.42 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Crider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.